한글목차

주요우울장애(MDD)는 세계에서 가장 흔한 정신질환 중 하나이며, 단발성 또는 반복적인 대우울증 에피소드(MDE)를 특징으로 합니다. 우울증 에피소드는 경험한 증상의 수와 심각도에 따라 경증, 중등도 또는 중증으로 분류됩니다. 또한, 각 중증도의 환자 중 일부는 치료 저항성으로 분류되는데, 이는 일반적으로 환자가 최소 두 번의 항우울제 치료에 반응하지 않는 경우로, MDD는 재발성 질환이며, 많은 환자들에게 첫 번째 우울증 에피소드는 심리사회적 기능에 심각한 장애를 동반하는 재발성, 쇠약성 만성 질환으로 발전합니다. 질환으로 발전합니다.

MDD의 관리에는 환자가 처음 치료를 받을 때부터 우울증 증상이 완화될 때까지의 급성 단기 치료와 완전하고 지속적인 기능적 회복을 시도하는 동시에 증상의 재발을 방지하는 장기 유지 요법이 포함됩니다. 항우울제 치료를 강화하기 위해 추가할 수 있는 다른 약물도 있습니다.

이 보고서는 주요우울장애(MDD) 시장을 조사했으며, 질환 개요, 역학, 질병 관리, 경쟁 평가, 미충족 수요, R&D 전략, 현재 및 향후 진출 기업, 시장 전망 등의 정보를 상세하게 정리하여 전해드립니다.

목차

제1장 주요우울장애(MDD) : 주요 요약

제2장 서론

제3장 질환 개요

제4장 역학

제5장 질병 관리

제6장 경쟁력 평가

제7장 미충족 요구와 기회 평가

제8장 연구개발 전략

제9장 파이프라인 평가

제10장 파이프라인 평가 분석

제11장 현재 및 향후 참여 기업

제12장 시장 전망

제13장 부록

영문목차

Abstract

The report provides an in-depth assessment of the MDD market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.

The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.

Key Highlights

• Forecast includes the 8 major markets (8MM)
• Forecast covers the period 2019-2029

Scope

• Overview of major depressive disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three adult patient segments (mild, moderate, and severe) from 2019 to 2029.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD therapy. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Major Depressive Disorder: Executive Summary - Updated Nov 2023, based on events up to Oct 31, 2023

2. Introduction - Updated Nov 2023, based on events up to Oct 31, 2023

3. Disease Overview - Updated Nov 2023, based on events up to Oct 31, 2023

4. Epidemiology

5. Disease Management - Updated Nov 2023, based on events up to Oct 31, 2023

6. Competitive Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

7. Unmet Needs and Opportunity Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

8. R&D Strategies - Updated Nov 2023, based on events up to Oct 31, 2023

9. Pipeline Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

10. Pipeline Valuation Analysis - Updated Nov 2023, based on events up to Oct 31, 2023

11. Current and Future Players - Updated Nov 2023, based on events up to Oct 31, 2023

12. Market Outlook - Updated Nov 2023, based on events up to Oct 31, 2023

13. Appendix - Updated Apr 2023, based on events up to Apr 13, 2023